A new study offers the first evidence of a drug capable of preventing lethal damage to the gastrointestinal (GI) tract caused by exposure to high levels of ionizing radiation, such as those occurring during a nuclear incident.
Memorial Sloan Kettering and IBM have agreed to collaborate on the development of a powerful tool built upon IBM Watson to provide medical professionals with improved access to comprehensive cancer data and practices.
Researchers have identified a set of genetic abnormalities in patients with acute myelogenous leukemia (AML) that doctors can use to more accurately predict patients’ prognoses and select treatments that are most likely to benefit them. The study, led by investigators at Memorial Sloan Kettering Cancer Center, will be published in the March 22 issue of the New England Journal of Medicine.
A rarely seen phenomenon in cancer patients — in which focused radiation to the site of one tumor is associated with the disappearance of metastatic tumors all over the body — has been reported in a patient with melanoma treated with the immunotherapeutic agent ipilimumab (Yervoy™).
For the first time, a new study has shown that removing polyps by colonoscopy not only prevents colorectal cancer from developing, but also prevents deaths from the disease. Patients in the study were evaluated for up to 23 years after having the procedure, providing the longest follow-up results to date.
More than 10,000 people nationwide will participate in Memorial Sloan Kettering Cancer Center’s sixth annual Cycle for Survival event taking place this February at Equinox clubs in New York City, Long Island, Washington D.C., Chicago, San Francisco, and Los Angeles.
As a tribute to Memorial Sloan Kettering Board member Josephine “Josie” Robertson, Memorial Sloan Kettering has joined with The Robertson Foundation to undertake two high-profile initiatives — the Josie Robertson Surgery Center and the Josie Robertson Investigators Program — made possible by a $50 million commitment from The Robertson Foundation.